<DOC>
	<DOCNO>NCT02941354</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial evaluate pharmacokinetics ( exposure trial drug body ) NovoEight® ( turoctocog alfa ) relation BMI ( body mass index ) subject haemophilia A .</brief_summary>
	<brief_title>Evaluating Pharmacokinetics NovoEight® ( Turoctocog Alfa ) Relation BMI Subjects With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male , age least 18 year time signing informed consent History 75 exposure day factor VIII product Subjects diagnosis congenital haemophilia A factor VIII activity 1 % , base medical record Known history factor VIII inhibitor Inhibitors factor VIII ( equal 0.6 BU ( Bethesda unit ) ) screen measure Nijmegen modify Bethesda method Known congenital acquire coagulation disorder haemophilia A Previous participation pharmacokinetic session turoctocog alfa another trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>